A mouse study presented at Digestive Disease Week 2026 reveals that restoring an aging body's own youthful gut bacteria can dramatically slow liver damage, reduce inflammation, and prevent cancer development. The finding suggests the microbiome plays a far more direct role in aging and disease than scientists previously understood.
Researchers at The University of Texas Medical Branch collected fecal samples from young mice and preserved them as the animals aged. Years later, they transplanted the stored material back into those same older mice through a procedure called fecal microbiota transplantation, or FMT. A control group of aging mice received sterilized samples instead.
The results were striking. None of the mice receiving their restored youthful microbiome developed liver cancer. By contrast, two out of eight untreated aging mice developed tumors. The treated group also showed significantly lower inflammation and reduced liver injury markers.
"We're learning from this work that the aging microbiome actively contributes to liver dysfunction and cancer risk rather than simply reflecting the aging process," said Qingjie Li, associate professor of gastroenterology and hepatology and the study's lead researcher. "The microbiome has a broader influence on the body's cancer defenses than previously understood."
Deeper investigation into liver tissue samples revealed critical molecular changes. Researchers examined MDM2, a gene associated with liver cancer development. Young mice naturally had low levels of the MDM2 protein. Untreated aging mice showed dramatically higher levels, but older mice that received the restored microbiome showed suppressed MDM2 levels closer to those of younger animals.
Dr. Li explained that the intervention reversed "several core features of aging at both the molecular and functional level, including inflammation, fibrosis, mitochondrial decline, telomere attrition, and DNA damage."
The discovery emerged almost accidentally. Researchers were initially studying the microbiome's effects on heart health when they noticed the microbiome alterations produced even stronger effects in liver tissue than in cardiac tissue. That unexpected finding prompted them to investigate the liver connection more thoroughly.
To minimize the risk of immune complications or infection in the mice, the team used each animal's own preserved microbiome rather than donor samples from other animals. This approach also creates a cleaner model for potential future human studies, the researchers noted.
Dr. Li cautioned that the work remains in the animal research phase and cannot yet be applied to humans. However, he said the team hopes to launch first-in-human clinical trials in the coming years.
Author Jessica Williams: "If this holds up in humans, we're looking at a potential game-changer for preventing both liver cancer and age-related disease, with nothing more exotic than your own preserved microbiome as the treatment."
Comments